In the current issue of Cardiovascular Innovations and Applications, researchers Ahmed Kheiwa, Anushree Agarwal and Anitha John from the Division of Cardiology, Department of Medicine, University of ...

Patients who have had surgery to create a Fontan circulation show changes in their genetic code, which may provide a new treatment opportunity to reduce premature aging. The procedure is used to treat ...

DALLAS, July 1, 2019 -- The Fontan procedure has allowed more people born with only one ventricle -- the lower pumping chamber of the heart -- to survive into adulthood, but their unique circulatory ...

A multi-center study has identified critical risk factors that increase the likelihood of death in children with a heart defect who are awaiting or have recently undergone heart transplantation, ...

Of the thousands of children born each year with congenital heart defects, a small cohort have severe malformations of their cardiac chambers leading to a single ventricle physiology. The current ...

Pediatric heart specialists in the Single Ventricle Care Program provide expert consultation and treatment of the unique issues that arise after the Norwood, Glenn and Fontan operations. For example, ...

Mezzion Pharmaceuticals, Inc. (Mezzion), a late-stage rare disease biopharmaceutical company developing the first potential treatment for people born with single ventricle congenital heart disease (SV ...

PHILADELPHIA — In a phase 3 study, the phosphodiesterase-5 (PDE-5) inhibitor udenafil (Mezzion Pharma) did not improve the primary end point of oxygen consumption at peak exercise, but was associated ...

SEOUL, South Korea, Aug. 12, 2025 /PRNewswire/ -- A newly published post-hoc analysis of the landmark FUEL (Fontan Udenafil Exercise Longitudinal) Trial demonstrates that udenafil, a PDE5 inhibitor, ...

Single ventricular defects of the heart occur in 5 out of 100,000 live births. This type of congenital heart defect does not provide a sustainable circulatory system for the patients affected.